Clinical Trial Update: Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of an individualized mRNA cancer vaccine targeting neoantigens in autologous tumors; study terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Melanoma

Drugs mentioned

• Autologous mRNA cancer vaccine (neoantigen vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Colon Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-04-24